EQS-News
Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives - Seite 2
However, for Biotest AG, the concept of sustainability holds a deeper meaning: "Biotest actively promotes sustainability, considering not only ecological aspects but also placing great value on social responsibility," emphasizes Dirk Neumüller, Head of Sustainability Management. "We are proud to be an employer in the Dreieich region and to provide our employees with secure jobs under good working conditions. Through our activities, we contribute to the economic stability of the region while simultaneously strengthening the secure access to life-saving medications for patients. Sustainability always remains at the center of our actions, which is why we are committed to reconciling both ecological and social aspects in order to make a positive impact."
About Biotest:
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
IR contact
Dr Monika Buttkereit
Lesen Sie auch
Phone: +49-6103-801-4406
Mail: ir@biotest.com
PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Preference shares: securities’ ID No. 522723; ISIN: DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hannover, München, Stuttgart, Tradegate
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These
statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of
actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.